Tag Archives: Myriad

Bhagat v. Iancu – Did the Myriad Decision Overrule Funk Bros.?

Posted on September 10, 2018 by Warren Woessner

A September 6th post by Dennis Crouch at PatentlyO (“A Mixture of Known Compounds is Unpatentable without a Transformation“) led me to a closer reading of the cert. petition filed in Bhagat v. Iancu, (Case No. 18-277) an appeal from … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | Leave a comment

Ex Parte Smith: What We’ve Got Here Is A Failure To Communicate!

Posted on May 29, 2018 by Warren Woessner

In Ex parte Smith, Appeal No. 2016-007565 (PTAB, May 16, 2016), the Board reversed the examiner’s s.101 and 103 rejections of a claim to a modified flavivirus envelop (E) protein comprising a mutated envelop protein, where the unmodified E-To domain … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment

New Webinar Series: Practical IP for Natural Sciences

Posted on August 23, 2017 by Warren Woessner

Please join us in a new webinar series directed to the practical strategies in a new era of patent law to protect IP in chemistry, pharmaceuticals, biotechnology and genetic medicine. The collision of new technologies and patent statutes of a … Continue reading →

Posted in Webinar | Tagged , , , , , , | Leave a comment

Athena Diagnostics, Inc. v. Mayo (D. Mass., August 4, 2017) – “That’s all,” She Wrote.

Posted on August 21, 2017 by Warren Woessner

Please read my recent post about stage 1 of this proceeding, in which the Judge in 2016 found that the claims to diagnosing Myasthemia Gravis (MG) by adding MuSk to a patient sample and detecting any IgG autoantibody complexes that … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment